Complete atrioventricular block associated with rivastigmine therapy

Basit Öğe Kaydı
dc.contributor.authorKayrak, Mehmet
dc.contributor.authorYazici, Mehmet
dc.contributor.authorAyhan, Selim S.
dc.contributor.authorKoc, Fatih
dc.contributor.authorUlgen, Mehmet S.
dc.date.accessioned2020-03-26T17:26:33Z
dc.date.available2020-03-26T17:26:33Z
dc.date.issued2008
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose. A case of complete atrioventricular block associated with rivastigmine use is presented. Summary. A 67-year-old Turkish woman with Alzheimer's disease was admitted to the hospital because of dizziness and syncope. Her medical history included diagnoses of hypertension (treated with amlodipine 5 mg daily) and diabetes mellitus (treated with nateglinide 120 mg daily). She had been taking both drugs for over five years. She had also been taking rivastigmine 6 mg p.o. daily for five months for the treatment of Alzheimer's disease. She had experienced dizziness since the onset of rivastigmine therapy but had not reported it to any health care provider. On admission, she had a blood pressure measurement of 90/60 mm Hg and a pulse rate of 34 beats/min. A 12-lead electrocardiogram revealed complete atrioventricular block. Echocardiography results, blood electrolyte levels, and cardiac biochemical markers were normal. After initial evaluation, a temporary transvenous pacemaker was implanted via the right femoral vein. Amlodipine and rivastigmine were discontinued. On the first day of hospitalization, a coronary angiogram revealed normal coronary anatomy. Two days later, the complete atrioventricular block resolved spontaneously to sinus rhythm. Rivastigmine 6 mg p.o. daily was reinitiated, and complete atrioventricular block recurred on the fourth day of therapy. A VVI permanent pacemaker was implanted on the fifth day of hospitalization. Amlodipine and rivastigmine were reinitiated. The patient continued rivastigmine 6 mg p.o. daily after permanent pacemaker implantation. A three-month follow-up appointment revealed that no further syncope episodes or dizziness had occurred. Conclusion. A 67-year-old woman developed complete atrioventricular block after receiving rivastigmine for the treatment of Alzheimer's disease.en_US
dc.identifier.doi10.2146/ajhp070230en_US
dc.identifier.endpage1053en_US
dc.identifier.issn1079-2082en_US
dc.identifier.issue11en_US
dc.identifier.pmid18499878en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1051en_US
dc.identifier.urihttps://dx.doi.org/10.2146/ajhp070230
dc.identifier.urihttps://hdl.handle.net/20.500.12395/22278
dc.identifier.volume65en_US
dc.identifier.wosWOS:000256267700015en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAMER SOC HEALTH-SYSTEM PHARMACISTSen_US
dc.relation.ispartofAMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAlzheimer diseaseen_US
dc.subjectamlodipineen_US
dc.subjectatrioventricular blocken_US
dc.subjectdrugs, adverse reactionsen_US
dc.subjectgeriatricsen_US
dc.subjectnateglinideen_US
dc.subjectpacemakersen_US
dc.subjectparasympathomimetic agentsen_US
dc.subjectrivastigmineen_US
dc.titleComplete atrioventricular block associated with rivastigmine therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu